SOLVONIS THERAPEUTICS PLC, a company operating within the Health Care sector, is listed on the London Stock Exchange. As of November 5, 2026, the company’s close price was recorded at 0.1 GBX. Over the past year, the stock has experienced significant fluctuations, with a 52-week high of 0.334 GBX on January 6, 2026, and a 52-week low of 0.09 GBX on November 5, 2026. The market capitalization of SOLVONIS THERAPEUTICS PLC stands at 9,163,604.1 GBX.
The company’s financial metrics indicate a Price Earnings (P/E) ratio of -1.22, suggesting that it is currently not generating profits. This negative P/E ratio is a critical point of interest for investors, as it reflects the company’s current financial performance and potential future profitability.
SOLVONIS THERAPEUTICS PLC is distinct from Graft Polymer UK PLC, which operates in the Materials sector and is based in London. Graft Polymer UK PLC specializes in providing chemical products, specifically polymer composite materials used in the production of polymer modifiers and alloys. These materials are designed to combine immiscible and incompatible components of polymers, resulting in a diverse range of mechanical properties, including chemical resistance and fire-retardant characteristics. Graft Polymer UK PLC serves a global customer base.
The information provided highlights the current financial standing and market performance of SOLVONIS THERAPEUTICS PLC, alongside a brief overview of Graft Polymer UK PLC’s operations and offerings. Investors and stakeholders are encouraged to consider these details when evaluating the potential and risks associated with SOLVONIS THERAPEUTICS PLC.
